Most Read Articles
Audrey Abella, 15 May 2020
In adults with atrial fibrillation (AF) after percutaneous coronary intervention (PCI), dual therapy (direct oral anticoagulant [DOAC] + P2Y12 inhibitor) reduces the risk of bleeding compared with triple therapy (vitamin K antagonist [VKA] + DAPT* [aspirin and P2Y12 inhibitor]), a meta-analysis has shown. However, its effects on the risks of mortality and ischaemic endpoints** remain unclear.
09 May 2020
Use of aspirin during the implantation window of the menstrual cycle appears to increase fecundability, reveals a recent study.
Rachel Soon, 08 Apr 2020

Guidelines for local pharmacists on what actions to take during the COVID-19 pandemic have been issued by the Malaysian Pharmaceutical Society (MPS).

Elaine Soliven, 20 May 2020
Early treatment with a triple antiviral combination of lopinavir-ritonavir, ribavirin, and interferon beta-1b significantly shortens the duration of virus shedding and reduces symptoms in patients with mild-to-moderate COVID-19 compared with lopinavir-ritonavir only, according to a recent study.

Delayed denosumab injections tied to reduced BMD response

13 Apr 2020

Delays in injections of denosumab lead to suboptimal bone mineral density (BMD) response at both spine and total hip, results of a recent study have shown.

Electronic medical records from two academic hospitals from 2010 to 2017 were used to examine the association between delayed denosumab infections and BMD change. Patients aged >45 years who used at least two doses of 60-mg denosumab were included in the analysis.

Medication coverage ratio (MCR) was utilized to assess adherence to denosumab. Good adherence was defined as a dosing interval ≤7 months (MCR ≥93 percent), moderate adherence an interval of 7–10 months (MCR 75–93 percent), and poor adherence an interval ≥10 months (MCR ≤75 percent).

Annualized percent BMD change at the lumbar spine, total hip and femoral neck from baseline was the primary outcome.

A total of 938 denosumab injections among 151 patients (mean age, 69 years; 95 percent female) were identified. Good adherence among patients resulted in a 3.9-percent annualized BMD increase at the lumbar spine compared with 3.0 percent for moderate or 1.4 percent for poor adherence (ptrend=0.002).

In addition, those with good adherence showed a 2.1-percent annualized BMD increase at the total hip compared with 1.3 percent for moderate or 0.6 percent for poor adherence (ptrend=0.002).

“Discontinuation of denosumab leads to a rapid reversal of its therapeutic effect,” the authors said. “Strategies to improve the timely administration of denosumab in real-world settings are needed.”

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Audrey Abella, 15 May 2020
In adults with atrial fibrillation (AF) after percutaneous coronary intervention (PCI), dual therapy (direct oral anticoagulant [DOAC] + P2Y12 inhibitor) reduces the risk of bleeding compared with triple therapy (vitamin K antagonist [VKA] + DAPT* [aspirin and P2Y12 inhibitor]), a meta-analysis has shown. However, its effects on the risks of mortality and ischaemic endpoints** remain unclear.
09 May 2020
Use of aspirin during the implantation window of the menstrual cycle appears to increase fecundability, reveals a recent study.
Rachel Soon, 08 Apr 2020

Guidelines for local pharmacists on what actions to take during the COVID-19 pandemic have been issued by the Malaysian Pharmaceutical Society (MPS).

Elaine Soliven, 20 May 2020
Early treatment with a triple antiviral combination of lopinavir-ritonavir, ribavirin, and interferon beta-1b significantly shortens the duration of virus shedding and reduces symptoms in patients with mild-to-moderate COVID-19 compared with lopinavir-ritonavir only, according to a recent study.